Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9327518 | 0.72 | HSD17B10 (0.41) | HSD17B10KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL30019143 | 0.70 | CYP19A1 (0.53) | HSD17B10KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL2905322 | 0.70 | AHR (0.49) | HSD17B10LMNACA12CA1CA2 | |
| SCHEMBL86321 | 0.70 | CYP19A1 (0.53) | HSD17B10KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL1137855 | 0.69 | GRM5 (0.48) | NR3C2MMP12PARP1 | |
| SCHEMBL279553 | 0.69 | CYP11B1 (0.56) | NR3C2CYP11B1CYP11B2KMT2AKDM4E | |
| SCHEMBL16254014 | 0.69 | HSD17B10 (0.46) | HSD17B10SIRT1LMNACA12CA1 | |
| SCHEMBL4095480 | 0.69 | MMP12 (0.44) | NR3C2KMT2AMMP12PARP1HTR1A | |
| SCHEMBL4897580 | 0.69 | GAA (0.39) | HSD17B10KDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL3488166 | 0.69 | NR3C2 (0.54) | NR3C2KMT2AKDM4EMMP12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-0441539-B1 | Thiazine (or oxazine) derivatives and preparation thereof | TANABE SEIYAKU CO (JP) | 1996-04-10 | — | — | EP | disclosed |
| US-5496815-A | TREATMENT OF ISCHEMIC ENCEPHALOPATHIA | TANABE SEIYAKU CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5281592-A | Calcium antagonist, antiischemic agents, brains, nervous system disorders | TANABE SEIYAKU CO., LTD. (JP) | 1994-01-25 | — | — | US | disclosed |
| US-5246929-A | Prophylaxis or treatment of ischemic encephalopathia | TANABE SEIYAKU CO., LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| EP-0441539-A2 | Thiazine (or oxazine) derivatives and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | NOD1, NLRP3, SLC10A1 | NR3C2 775/4885CYP11B1 309/4885CYP11B2 383/4885 |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | NUDT1, NOD1, SLC28A1 | NR3C2 1019/4885CYP11B1 1242/4885CYP11B2 1920/4885 |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | NOD1, XDH, URB2 | NR3C2 701/4885CYP11B1 758/4885CYP11B2 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.